Lensar, Inc. · NASDAQ:LNSR
Lensar — Investor Presentation (August 2026)
18 slides from Lensar's investor presentation, August 2026
Slide 1: Combining Robotic Intelligence and Precision with Surgeon Expertise
August 2026 Combining Robotic Intelligence and Precision with Surgeon Expertise
Slide 2: Disclaimer
DISCLAIMER This presentation includes estimates regarding market and industry data. Unless otherwise indicated, information concerning the industry and the markets in which LENSAR, Inc. (the “Company,” “we,” “our” or “us”) operates, including management’s general expectations, market position, marke
Slide 3: Why LENSAR
WHY LENSAR Leading Laser Cataract Surgery Innovator In Growing Cataract Procedure Market Large Growing TAM • Cataract Surgery : ~33M procedures worldwide in forecasted 20261 • Significant Unmet Need; 22-29 M with treatable astigmatism – majority go untreated1,2 • Laser Cataract Surgery (LCS): ~1.2M
Slide 4: Patients Prefer Robotic Laser Cataract Surgery
PATIENTS PREFER Robotic Laser Cataract of patients said they Surgery13 would choose a surgeon Patients who said they would prefer to have Robotic Laser Cataract Surgery said it would make them feel: 60% who performed robotic laser cataract surgery over one who didn’t. Calm Confident Assured 4
Slide 5: Most Advanced Cataract Procedure
MOST ADVANCED CATARACT PROCEDURE Only ALLY Robotic Laser Cataract Surgery® combines robotic intelligence and precision with surgeon expertise to deliver the most advanced cataract procedure available. 5
Slide 6: Workflow Efficiencies: Significant Time Savings
WORKFLOW EFFICIENCIES Significant Time Savings14 5:18 18:49 51:27 MINUTES MINUTES MINUTES Surgeon Savings Staff Savings Patient Savings Competitive System 15:50 Competitive System 49:11 Competitive System 1:21:40 ALLY® 10:32 ALLY® 30:22 ALLY® 30:22 6
Slide 7: Your ALLY in Workflow to Increase Your Bottom Line
YOUR ALLY® IN WORKFLOW TO INCREASE YOUR BOTTOM LINE ASC Increase Savings4-6 Revenue4,6-10 Decrease ASC Increase $11.4k/Day $9k - $12k/Day $405k - $540k/Year ASC Hours Or Pt Treated $513.5k/Year 90 – 120 MIN/Day 10 More Surgeon Cases /Day $10.8k/Day $487.8k/Year “Our practice increased our conversion
Slide 8: Prior LenSx Users
PRIOR LenSx USERS No surgeon was compensated to provide a quote; however, some of these surgeons are LENSAR consultants. 8
Slide 9: Prior Catalys Users
PRIOR Catalys USERS No surgeon was compensated to provide a quote; however, some of these surgeons are LENSAR consultants. 9
Slide 10: Evidence That ALLY Is Expanding the LACS Market
EVIDENCE THAT ALLY IS EXPANDING THE LACS MARKET NEW LASER UNIT SHARE – LAST 12 MONTHS15 2.0% 5.0% 7.0% 27.0% Nearly 40% of lasers installed in 20.0% last year (Q3 25 – Q2 2026) were at sites that never used a femtosecond laser, thereby expanding the LACS market15 39.0% LENSAR (LLS) New/Naïve LenSx C
Slide 11: Evidence That LENSAR Is Expanding the LACS Market
EVIDENCE THAT LENSAR IS EXPANDING THE LACS MARKET ~40% of all lasers installed since Q3 2025, were in new or LACS-naïve customers15 LENSAR Lasers perform 31% more procedures1, 16 11
Slide 12: LENSAR Has Significantly Increased LACS Procedure Share
LENSAR HAS SIGNIFICANTLY INCREASED LACS PROCEDURE SHARE3 26.0% 24.0% 10% Increase in 24.1% 23.4% 23.4% 22.0% Procedure Share Since 21.8% 21.4% 21.8% 20.0% ALLY Launch 19.9% 20.4% 18.0% 18.4% 18.4% 16.0% 16.4% 16.9% 15.0% 15.6% 14.4% 14.0% 13.5% 14.0% 14.1% 12.0% 10.0% 8.0% Q3 2024 Q4 2024 Q1 2022 Q2
Slide 13: Procedure Volume
PROCEDURE VOLUME 13% 70,000 Global growth 76% vs. Q2 2025 58,682 60,000 Global growth 54,756 54,094 52,347 52,100 since ALLY launch 50,000 45,586 46,811 42,203 42,231 41,074 38,901 39,486 39,457 40,000 35,349 37,414 37,023 33,359 32,649 33,007 33,249 33,091 31,400 31,600 31,616 28,453 28,666 30,000
Slide 14: Global Installed Base
GLOBAL INSTALLED BASE 9% 500 growth vs. Q2 2025 445 450 425 435 440 410 400 71% 385 395 growth since 355 350 330 ALLY launch 305 310 295 300 271 275 285 255 260 260 250 200 150 100 50 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 2022 2022 2022 2022 2023 2023 2023 2023 2024 2024 2024 2024
Slide 15: Revenue Results and Metrics
REVENUE RESULTS AND METRICS $ in thousands Three Months Ended Six Months Ended June 30, June 30, 2026 2025 2026 2025 Revenue System $ 2,809 $ 2,576 $ 3,645 $ 5,208 Recurring revenue: Procedure 10,233 8,334 19,473 16,620 Lease 1,772 1,645 3,453 3,529 Service 1,681 1,380 3,352 2,737 Total recurring re
Slide 16: Financial Information
FINANCIAL INFORMATION $ in millions Three Months Ended Six Months Ended June 30, June 30, 2026 2025 2026 2025 Revenue $ 16.5 $ 13.9 $ 29.9 $ 28.1 % Change 18% 10% 7% 21% Net income (loss) $ 3.5 $ (1.8) $ 39.9 $ (29.1) EBITDA1 $ 4.5 $ (0.9) $ 41.8 $ (27.3) Add: Stock-based compensation expense $ 0.3
Slide 17: Non-GAAP Reconciliation
NON-GAAP RECONCILIATION $ in thousands Three Months Ended Six Months Ended June 30, June 30, 2026 2025 2026 2025 Net income (loss) $ 3,535 $ (1,764) $ 39,867 $ (29,109) Less: Interest income (171) (193) (316) (352) Add: Depreciation expense 878 865 1,782 1,709 Add: Amortization expense 228 230 457 4
Slide 18: References
References: 1. 2026 Cataract Surgical Equipment Market Report. Market Scope. July 2026. 2. Dr. Warren Hill. Assumes mid-range distribution of pre-op corneal astigmatism. Excludes irregular and other conditions that impact toric selection. 3. Market Scope Ophthalmic Manufacturer’s Report Q2 2026 4. T